Core Points - The FDA announced a recall of over 580,000 bottles of the antihypertensive drug prazosin hydrochloride due to contamination with potential carcinogenic substances [1] - The recall was initiated by Teva Pharmaceuticals USA and Aurobindo Pharma USA earlier this month as a voluntary nationwide action [1] - The drug is used for vasodilation and lowering blood pressure, and is also commonly prescribed for nightmares and sleep issues related to PTSD [1] - The FDA classified this recall as a "Class II recall," indicating a moderate risk to health [1] Company Summary - Teva Pharmaceuticals USA and Aurobindo Pharma USA are the companies involved in the recall of prazosin hydrochloride [1] - The recall affects multiple batches of the drug, which may contain N-nitrosamine impurities formed during production or storage [1] Industry Summary - The incident highlights ongoing concerns regarding drug safety and contamination in the pharmaceutical industry [1] - Regulatory scrutiny is increasing as the FDA continues to monitor and address potential carcinogenic risks in medications [1]